“and I expect that momentum to continue.”

In context

“e primary endpoint, the secondary endpoint the MI subgroup, quite frankly the overall incidence of death in the trial was also something that attracted attention. From specialists. So the cardiology group has seen this as an affirmation of what they were already doing and being aggressive in treating LDL cholesterol. And primary care physicians, as I mentioned, are much more intent and aligned to adding Rupatha to the optimized statin therapy that most patients are on. As for how much we don't give product specific guidance. But hopefully you can tell I am extremely excited about the momentum that we have on Repatha right now. I'm really pleased with the execution of our teams around the world. We've made incremental investments in advance of the opportunity of promoting the Vesalius data and I expect that momentum to continue. Okay. Thank you. Let's go to the next question. Julianne: Thank you, Mohit. Our next question comes from Louise Chen from Scotiabank. Please go ahead. Your line is open. Louise Chen: Hi, thanks for taking my question. I wanted to ask you about TEPEZZA and your thoughts on another potential competitor coming to market and then also where you stand with AMG seven thirty two for TED. Thank you. Robert A. Bradway: Okay, great. Maybe again we could do this in two chunks. Jay, you want to talk about the clinical piece and then Mirko talk about the commercial piece? James E. Bradner: Thanks, Louise. TEPEZZA is proving to be just a very important medicine. For the management of thyroid eye disease. We have established a very strong evidence base in both the high clinical activity score and lower”